Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema cream showdown: steroid vs Non-Steroid in kids

NCT ID NCT07537751

Disease control Sponsor: Noura Abdelmoneim Mohammed Elseessy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two creams for mild to moderate eczema in 40 children aged 1-12. One cream was a steroid (fluticasone), the other a non-steroid (crisaborole). Both were applied twice daily for 6 weeks, then twice weekly for 12 weeks if the skin improved a lot. Both treatments worked well; the steroid worked faster, but the non-steroid showed a trend toward keeping eczema away longer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Crisaborole 2% ointment and fluticasone propionate 0.05% cream
What this could lead to
If successful, this could show that crisaborole is a good non-steroid option for children with eczema, possibly with fewer relapses than steroid creams.
What could go wrong
This was a small, completed trial with only 40 children, so results may not apply to all patients. The trend toward fewer relapses with crisaborole needs confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Feb 2024

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children of either sex aged 1 to 12 years. * Clinical diagnosis of atopic dermatitis based on Hanifin and Rajka criteria. * Mild to moderate disease with objective SCORAD up to 40. * Investigator's Static Global Assessment (ISGA) score of 2 (mild) or 3 (moderate) at baseline. Exclusion Criteria: * Use of systemic corticosteroids, nonsteroidal systemic immunosuppressants (e.g., cyclosporine, methotrexate), or phototherapy within 4 weeks before baseline. * Use of topical corticosteroids, transdermal corticosteroids, topical antibiotics, or any medicated topical agent within 1 week before baseline. * Severe atopic dermatitis (objective SCORAD \> 40). * Significant medical condition requiring systemic medication (e.g., cancer). * Current clinical diagnosis of bacterial skin infection (such as abscess or impetigo).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis Eczema

Contacts and locations

Locations

  • Faculty of Medicine, Kafr Elsheikh University

    Kafr ash Shaykh, Kafr el-Sheikh Governorate, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.